AltruBio Reports the Completion of Patient Enrollment in P-I Clinical Study of Neihulizumab (ALTB-168) for Steroid-Refractory Acute Graft-Versus-Host Disease
- The company has completed the patient enrollment in the P-I clinical study to evaluate PK, PD, safety & efficacy of neihulizumab (ALTB-168) in 24 patients with SR-aGVHD or aGVHD. The results are expected in the coming mos.
- ALTB-168 showed an improvement in patient outcomes with benefits across all organs including in difficult to treat GI disease. Additionally, 190 patients has been dosed in four different indications which showed that the therapy was well tolerated and demonstrated durable response outcomes
- The company plans to file an IND application of ALTB-168 in H2’22. ALTB-168 has been clinically validated across multiple inflammatory conditions including psoriasis, PsA, UC, and acute GVHD
Ref: Globe Newswire | Image: Altrubio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected]